{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.39","value":"1.0"},{"groupId":"OG001","spread":"0.22","value":"0.8"},{"groupId":"OG002","spread":"0.25","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.","dispersionType":"Standard Deviation","groups":[{"description":"LMB-100 100 mcg/kg\n\nLMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG000","title":"Dose Escalation Dose Level 1 LMB-100 100 mcg/kg"},{"description":"LMB-100 140 mcg/kg\n\nLMB-100: Arms 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG001","title":"Dose Escalation Dose Level 2 LMB-100 140 mcg/kg"},{"description":"LMB-100 at optimal dose plus tofacitinib - 100 mcg/kg LMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG002","title":"Dose Expansion LMB-100, 100 mcg/kg"}],"paramType":"MEAN","populationDescription":"3/16 participants were not analyzed because they did not have Plasma Half-life (T1/2) of LMB-100 measured during the 1st cycle (i.e., Not evaluable).","reportingStatus":"POSTED","timeFrame":"Pre-administration, end-of-infusion, then 1, 2, 4, 8-10, 12-16 hours post- LMB-100 during cycle 1 (each cycle = 21 days)","title":"Plasma Half-Life (T1/2) of LMB-100","type":"SECONDARY","unitOfMeasure":"hour (h)"}